Archived Newsletters
-
03.07.24 -- Is WuXi Apptec An Enemy Of The State?
3/7/2024
03/07/24 Outsourced Pharma Newsletter
-
03.06.24 -- A New Approach To Allogeneic Cell Therapy Process Development
3/6/2024
03/06/24 Outsourced Pharma Newsletter
-
03.06.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
3/6/2024
03/06/24 Outsourced Pharma Newsletter
-
03.05.24 -- New CRISPR Delivery Methods, Next-Generation Plasmid Vectors, And RNP Analytics For Reduced Off-Target Effects
3/5/2024
03/05/24 Outsourced Pharma Newsletter
-
03.05.24 -- What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry?
3/5/2024
03/05/24 Outsourced Pharma Newsletter
-
03.04.24 -- A Patient- And Planet-Centric Approach To Enhancing Medicines In Development
3/4/2024
03/04/24 Outsourced Pharma Newsletter
-
03.04.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
3/4/2024
03/04/24 Outsourced Pharma Newsletter
-
03.01.24 -- Is WuXi Apptec An Enemy Of The State?
3/1/2024
03/01/24 Outsourced Pharma Newsletter
- Best of February: Top 5 Insights in Outsourced Drug Development and Manufacturing 2/29/2024
-
02.29.24 -- Overcoming Hurdles On The Path To CGT Manufacturing
2/29/2024
02/29/24 Outsourced Pharma Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more